Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PFS better with trofosfamide than doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomas

Hartman JT et al. ASCO 2018, Abstract 11507.

Key clinical point: The oral alkylating agent trofosfamide showed efficacy in a small number of elderly patients with untreated metastatic soft-tissue sarcomas.

Major finding: In a randomized phase 2 trial that compared trofosfamide with doxorubicin (Adriamycin), the 6-month progression-free survival (PFS) rate with trofosfamide, the primary endpoint, was 27. 6% versus 35.9% in the doxorubicin arm.

Study details: Randomized phase 2 trial comparing trofosfamide with doxorubicin in 120 elderly patients with histologically confirmed metastatic soft-tissue sarcomas with no prior first-line chemotherapy and with adequate bone marrow, renal, and liver functionelderly patients with previously untreated .

Disclosures: The trial was supported by Baxter Oncology of Germany. Dr. Hartmann reported having no conflicts of interest to disclose.

Source: Hartman JT et al. ASCO 2018, Abstract 11507.

Citation:

Hartman JT et al. ASCO 2018, Abstract 11507.

This Week's Must Reads

Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.

Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030

Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005

Must Reads in Sarcoma & GIST